|
 Bayer plans to evaluate the blood-thinning drug, called ISIS-FXI, in
frail patients that cannot be given currently available drugs
because they are at high risk of bleeding.
While the drug is being tested for the prevention of thrombosis,
Bayer plans to look into further uses in the area of
anti-coagulation.
Under the agreement, Isis is eligible to an immediate $100 million
payment and a $55 million payment depending on the success of a
Phase II study in patients with compromised kidney function.
Isis also stands to receive milestone payments as the drug advances
to market as well as tiered royalties in the low to high twenty
percent range on gross margins of ISIS-FXI.
After completion of ongoing activities at Isis, Bayer will take over
all global clinical development as well as worldwide
responsibilities for seeking regulatory approval and marketing of
the compound.
[to top of second column] |
(Reporting by Ludwig Burger; Editing by Edward Taylor)
[© 2015 Thomson Reuters. All rights
reserved.] Copyright 2015 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.
 |
